CANCER RESEARCH INSTITUTE, INC.

FINANCIAL STATEMENTS

JUNE 30, 2022 and 2021
## Contents

<table>
<thead>
<tr>
<th>Independent Auditors’ Report</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Financial Statements</strong></td>
<td></td>
</tr>
<tr>
<td>Statements of financial position as of June 30, 2022 and 2021</td>
<td>3</td>
</tr>
<tr>
<td>Statements of activities for the years ended June 30, 2022 and 2021</td>
<td>4</td>
</tr>
<tr>
<td>Statement of functional expenses for the year ended June 30, 2022 (with summarized financial information for 2021)</td>
<td>5</td>
</tr>
<tr>
<td>Statement of functional expenses for the year ended June 30, 2021</td>
<td>6</td>
</tr>
<tr>
<td>Statements of cash flows for the years ended June 30, 2022 and 2021</td>
<td>7</td>
</tr>
<tr>
<td>Notes to financial statements</td>
<td>8</td>
</tr>
</tbody>
</table>
INDEPENDENT AUDITORS' REPORT

Board of Trustees
Cancer Research Institute, Inc.

Report on the Financial Statements

Opinion

We have audited the financial statements of the Cancer Research Institute, Inc. (the "Institute"), which comprise the statements of financial position as of June 30, 2022 and 2021, and the related statements of activities, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Cancer Research Institute, Inc. as of June 30, 2022 and 2021, and the changes in its net assets and its cash flows for each of the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (“GAAS”). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

The Institute’s management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute’s ability to continue as a going concern for one year after the date that the financial statements are available to be issued.
Auditors’ Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute’s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Institute’s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

EisnerAmper LLP
New York, New York
September 23, 2022
### Statements of Financial Position

#### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$12,037,142</td>
<td>$33,017,941</td>
</tr>
<tr>
<td>Contributions and grants receivable, net</td>
<td>27,637,473</td>
<td>37,197,576</td>
</tr>
<tr>
<td>Bequests receivable</td>
<td>10,189</td>
<td>12,090</td>
</tr>
<tr>
<td>Other receivables</td>
<td>39,970</td>
<td>109,931</td>
</tr>
<tr>
<td>Investments</td>
<td>89,475,600</td>
<td>74,840,482</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>142,209</td>
<td>144,870</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>426,189</td>
<td>418,519</td>
</tr>
<tr>
<td>Beneficial interest in perpetual trust</td>
<td>669,540</td>
<td>806,477</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$130,438,312</strong></td>
<td><strong>$146,547,886</strong></td>
</tr>
</tbody>
</table>

#### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$565,065</td>
<td>$849,150</td>
</tr>
<tr>
<td>Paycheck Protection Program loan payable</td>
<td>-</td>
<td>710,150</td>
</tr>
<tr>
<td>Grants and fellowships payable, net</td>
<td>62,989,463</td>
<td>70,340,459</td>
</tr>
<tr>
<td>Deferred rent obligation</td>
<td>100,537</td>
<td>110,670</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>78,485</td>
<td>81,822</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>63,733,550</strong></td>
<td><strong>72,092,251</strong></td>
</tr>
</tbody>
</table>

Commitments and other uncertainty (see Notes C and N)

Net Assets:

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undesignated and available for general activities</td>
<td>36,886,364</td>
<td>42,980,717</td>
</tr>
<tr>
<td>Board-designated as endowment</td>
<td>5,614,906</td>
<td>5,931,228</td>
</tr>
<tr>
<td><strong>Total net assets without donor restrictions</strong></td>
<td><strong>42,501,270</strong></td>
<td><strong>48,911,945</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>With donor restrictions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purpose restrictions</td>
<td>20,655,562</td>
<td>21,858,823</td>
</tr>
<tr>
<td>Perpetual in nature</td>
<td>3,547,930</td>
<td>3,684,867</td>
</tr>
<tr>
<td><strong>Total net assets with donor restrictions</strong></td>
<td><strong>24,203,492</strong></td>
<td><strong>25,543,690</strong></td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>66,704,762</strong></td>
<td><strong>74,455,635</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$130,438,312</strong></td>
<td><strong>$146,547,886</strong></td>
</tr>
</tbody>
</table>

See notes to financial statements.
CANCER RESEARCH INSTITUTE, INC.

Statements of Activities

Year Ended June 30,

<table>
<thead>
<tr>
<th></th>
<th>2022 Without Donor Restrictions</th>
<th>2022 With Donor Restrictions</th>
<th>2021 Without Donor Restrictions</th>
<th>2021 With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General and trustee</td>
<td>$ 9,607,596</td>
<td>$ 150,000</td>
<td>$ 9,757,596</td>
<td>$ 9,192,028</td>
<td>$ 9,192,028</td>
</tr>
<tr>
<td>Combined federal campaigns</td>
<td>559,676</td>
<td>-</td>
<td>559,676</td>
<td>580,051</td>
<td>580,051</td>
</tr>
<tr>
<td>Bequests and memorials</td>
<td>5,336,419</td>
<td>-</td>
<td>5,336,419</td>
<td>3,727,223</td>
<td>3,727,223</td>
</tr>
<tr>
<td>Special events</td>
<td>656,610</td>
<td>18,896</td>
<td>675,506</td>
<td>1,140,888</td>
<td>660</td>
</tr>
<tr>
<td>Designated contributions</td>
<td>10,336,547</td>
<td>1,357,771</td>
<td>11,694,318</td>
<td>13,993,437</td>
<td>4,235,700</td>
</tr>
<tr>
<td>Cancellation of grants</td>
<td>4,531,239</td>
<td>-</td>
<td>4,531,239</td>
<td>-</td>
<td>18,229,137</td>
</tr>
<tr>
<td>Donated services</td>
<td>543,693</td>
<td>-</td>
<td>543,693</td>
<td>589,448</td>
<td>589,448</td>
</tr>
<tr>
<td>Total public support</td>
<td>31,571,780</td>
<td>1,526,667</td>
<td>33,098,447</td>
<td>29,223,075</td>
<td>33,459,435</td>
</tr>
<tr>
<td>Operating revenues:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rental income</td>
<td>21,476</td>
<td>-</td>
<td>21,476</td>
<td>-</td>
<td>17,981</td>
</tr>
<tr>
<td>Investment income allocation</td>
<td>3,121,803</td>
<td>-</td>
<td>3,121,803</td>
<td>2,931,434</td>
<td>2,931,434</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>72,651</td>
<td>-</td>
<td>72,651</td>
<td>87,868</td>
<td>87,868</td>
</tr>
<tr>
<td>Total operating support and revenues</td>
<td>3,215,930</td>
<td>-</td>
<td>3,215,930</td>
<td>3,037,283</td>
<td>3,037,283</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>2,149,562</td>
<td>(2,149,562)</td>
<td>-</td>
<td>(4,158,974)</td>
<td>(4,158,974)</td>
</tr>
<tr>
<td>Total operating support and revenues</td>
<td>36,937,272</td>
<td>(622,895)</td>
<td>36,314,377</td>
<td>77,386</td>
<td>36,496,718</td>
</tr>
<tr>
<td>Operating expenses:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration</td>
<td>1,635,888</td>
<td>-</td>
<td>1,635,888</td>
<td>1,510,413</td>
<td>1,510,413</td>
</tr>
<tr>
<td>Marketing and development</td>
<td>3,522,149</td>
<td>-</td>
<td>3,522,149</td>
<td>2,945,732</td>
<td>2,945,732</td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>5,083,246</td>
<td>-</td>
<td>5,083,246</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>10,241,283</td>
<td>-</td>
<td>10,241,283</td>
<td>4,456,145</td>
<td>4,456,145</td>
</tr>
<tr>
<td>Total expenses</td>
<td>36,472,872</td>
<td>(622,895)</td>
<td>36,419,987</td>
<td>77,386</td>
<td>36,496,718</td>
</tr>
<tr>
<td>Change in net assets from operating activities</td>
<td>464,400</td>
<td>(158,495)</td>
<td>496,007</td>
<td>77,386</td>
<td>573,393</td>
</tr>
<tr>
<td>Non-operating activities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net investment (loss) income in excess of investment allocation</td>
<td>(7,585,225)</td>
<td>(580,366)</td>
<td>(8,165,591)</td>
<td>12,362,685</td>
<td>1,032,293</td>
</tr>
<tr>
<td>Gain on loan forgiveness</td>
<td>710,150</td>
<td>-</td>
<td>710,150</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Change in value of perpetual trust</td>
<td>-</td>
<td>(136,937)</td>
<td>(136,937)</td>
<td>-</td>
<td>152,663</td>
</tr>
<tr>
<td>Total non-operating activities</td>
<td>(6,875,075)</td>
<td>(717,303)</td>
<td>(7,592,378)</td>
<td>12,362,685</td>
<td>1,184,956</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>(6,410,675)</td>
<td>(1,340,198)</td>
<td>(7,750,873)</td>
<td>12,884,692</td>
<td>1,262,342</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>48,911,945</td>
<td>25,543,690</td>
<td>74,455,635</td>
<td>36,053,253</td>
<td>24,281,348</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>42,501,270</td>
<td>24,203,492</td>
<td>66,704,762</td>
<td>48,911,945</td>
<td>25,543,690</td>
</tr>
</tbody>
</table>

See notes to financial statements.

4
# Statement of Functional Expenses

**Year Ended June 30, 2022**  
(with summarized financial information for 2021)

<table>
<thead>
<tr>
<th>Program Services</th>
<th>Support Services</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Science, Medical Research</td>
<td>5,538,593</td>
</tr>
<tr>
<td></td>
<td>and Research Communications Administration</td>
<td>$ -</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>5,538,593</td>
</tr>
<tr>
<td>Fellowship program</td>
<td>547,500</td>
<td>-</td>
</tr>
<tr>
<td>Diversity fellowship grants program</td>
<td>-</td>
<td>3,033,836</td>
</tr>
<tr>
<td>Designated grants program</td>
<td>3,033,836</td>
<td>-</td>
</tr>
<tr>
<td>Clinical accelerator program</td>
<td>-</td>
<td>547,500</td>
</tr>
<tr>
<td>Technology Prize Award</td>
<td>-</td>
<td>7,500,000</td>
</tr>
<tr>
<td>CLIP grants program</td>
<td>547,500</td>
<td>-</td>
</tr>
<tr>
<td>STAR Program</td>
<td>2,533,000</td>
<td>-</td>
</tr>
<tr>
<td>Professional fees and commissions</td>
<td>36,057,075</td>
<td>31,441,418</td>
</tr>
<tr>
<td>Printing, postage and supplies</td>
<td>2,175,205</td>
<td>246,722</td>
</tr>
<tr>
<td>Rent</td>
<td>2,597,930</td>
<td>58,151</td>
</tr>
<tr>
<td>Telephone</td>
<td>596,503</td>
<td>19,546</td>
</tr>
<tr>
<td>Advertising</td>
<td>416,569</td>
<td>996,244</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>7,500,000</td>
<td>3,198</td>
</tr>
<tr>
<td>Travel, catering, and related costs</td>
<td>42,814</td>
<td>17,228</td>
</tr>
<tr>
<td>Insurance expense</td>
<td>10,241,283</td>
<td>62,029</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>10,241,283</td>
<td>62,029</td>
</tr>
</tbody>
</table>

**Total expenses before allowance for uncollectible accounts**  
$4,083,694 | 22,147,895 | 26,231,589 | 1,771,204 | 3,522,149 | 5,293,353 | 31,524,942 | 36,057,075 |

**Allowance for uncollectible accounts**  
$5,083,246 | $5,083,246 | $5,083,246 |

**Total expenses per statements of activities**  
$4,083,694 | 22,147,895 | 26,231,589 | 6,719,134 | 3,522,149 | 10,241,283 | 36,472,872 | 35,923,325
## Statement of Functional Expenses
### Year Ended June 30, 2021

<table>
<thead>
<tr>
<th></th>
<th>Science, Medical and Research Information, and Communications</th>
<th>Support Services</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Research</td>
<td>Administration</td>
<td>Marketing and Development</td>
</tr>
<tr>
<td>Fellowship program</td>
<td>$ -</td>
<td>$ -</td>
<td>$ -</td>
</tr>
<tr>
<td>Designated grants program</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Clinical accelerator program</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Technology Prize Award</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CLIP grants program</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STAR Program</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Salaries, benefits and related taxes</td>
<td>1,994,181</td>
<td>1,994,181</td>
<td>1,058,085</td>
</tr>
<tr>
<td>Professional fees and commissions</td>
<td>1,395,153</td>
<td>1,395,153</td>
<td>129,176</td>
</tr>
<tr>
<td>Printing, postage and supplies</td>
<td>188,253</td>
<td>188,253</td>
<td>86,139</td>
</tr>
<tr>
<td>Rent</td>
<td>191,736</td>
<td>191,736</td>
<td>238,527</td>
</tr>
<tr>
<td>Telephone</td>
<td>10,009</td>
<td>10,009</td>
<td>10,008</td>
</tr>
<tr>
<td>Advertising</td>
<td>176,806</td>
<td>176,806</td>
<td>25</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>17,125</td>
<td>17,125</td>
<td>9,420</td>
</tr>
<tr>
<td>Travel, catering, and related costs</td>
<td>-</td>
<td>-</td>
<td>9,301</td>
</tr>
<tr>
<td>Insurance expense</td>
<td>-</td>
<td>-</td>
<td>55,832</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>15,870</td>
<td>15,870</td>
<td>45,650</td>
</tr>
<tr>
<td>Total expenses before allowance for uncollectible accounts</td>
<td>3,989,133</td>
<td>27,478,047</td>
<td>31,467,180</td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total expenses</td>
<td>3,989,133</td>
<td>27,478,047</td>
<td>31,467,180</td>
</tr>
<tr>
<td>Less: rent</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total expenses per statements of activities</td>
<td>$ 3,989,133</td>
<td>$ 27,478,047</td>
<td>$ 31,467,180</td>
</tr>
</tbody>
</table>

See notes to financial statements.
CANCER RESEARCH INSTITUTE, INC.

Statements of Cash Flows

<table>
<thead>
<tr>
<th>Year Ended June 30,</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
<td>2021</td>
</tr>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$(7,750,873)</td>
<td>$14,121,034</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donated securities</td>
<td>-</td>
<td>$(89,645)</td>
</tr>
<tr>
<td>Proceeds from sale of donated securities</td>
<td>-</td>
<td>89,645</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>45,164</td>
<td>42,814</td>
</tr>
<tr>
<td>Bad debt expense</td>
<td>5,083,246</td>
<td>-</td>
</tr>
<tr>
<td>Gain on loan forgiveness</td>
<td>$(710,150)</td>
<td>-</td>
</tr>
<tr>
<td>Net realized and unrealized loss (gains) on investments</td>
<td>5,123,589</td>
<td>$(17,096,248)</td>
</tr>
<tr>
<td>Change in value of beneficial interest in perpetual trust</td>
<td>136,937</td>
<td>$(152,663)</td>
</tr>
<tr>
<td>Deferred rent</td>
<td>$(10,133)</td>
<td>$(10,133)</td>
</tr>
<tr>
<td>Changes in:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions and grants receivable, net</td>
<td>4,476,857</td>
<td>226,679</td>
</tr>
<tr>
<td>Bequests receivable</td>
<td>1,901</td>
<td>74,565</td>
</tr>
<tr>
<td>Other receivables</td>
<td>69,961</td>
<td>123,876</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>$(7,670)</td>
<td>$(19,839)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$(284,085)</td>
<td>404,863</td>
</tr>
<tr>
<td>Grants and fellowships payable</td>
<td>$(7,350,996)</td>
<td>5,465,367</td>
</tr>
<tr>
<td>Other liabilities</td>
<td>$(3,337)</td>
<td>2,559</td>
</tr>
<tr>
<td><strong>Net cash (used in) provided by operating activities</strong></td>
<td>$(1,179,589)</td>
<td>3,182,874</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of office equipment</td>
<td>$(42,503)</td>
<td>$(25,104)</td>
</tr>
<tr>
<td>Purchases of long-term investments</td>
<td>$(32,629,200)</td>
<td>$(16,052,275)</td>
</tr>
<tr>
<td>Proceeds from sales of long-term investments</td>
<td>12,870,493</td>
<td>16,457,239</td>
</tr>
<tr>
<td><strong>Net cash (used in) provided by in investing activities</strong></td>
<td>$(19,801,210)</td>
<td>379,860</td>
</tr>
<tr>
<td><strong>Net change in cash and cash equivalents</strong></td>
<td>(20,980,799)</td>
<td>3,562,734</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning of year</td>
<td>33,017,941</td>
<td>29,455,207</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents, end of year</strong></td>
<td>$12,037,142</td>
<td>$33,017,941</td>
</tr>
<tr>
<td><strong>Supplemental disclosure of cash flow information:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donated services</td>
<td>$543,693</td>
<td>$589,448</td>
</tr>
</tbody>
</table>

See notes to financial statements.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES

[1] The Institute:

The Cancer Research Institute, Inc. (the "Institute") was founded in 1953 in New York to foster the field of cancer immunology, in the belief that the body's immune system can be used to control and cure cancer. The Institute supports research with the immediate aim of increasing the understanding of the immune system and with the ultimate goal of developing immunological methods for the prevention and treatment of human cancer. The Institute also functions as a definitive source of public information on cancer immunology and cancer treatment.

The Institute is a not-for-profit corporation exempt from federal income taxes pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

[2] Basis of accounting:

The financial statements of the Institute have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

[3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

[4] Operating measure:

Operating revenues and expenses reflect the activities in which the Institute typically engages to fulfill its mission. The Institute utilizes a spending rate in making its annual investment allocation for support of operations. Investment income, including net realized and unrealized gains and losses, earned in excess of or less than the Institute's spending rate as well as the change in the value of perpetual trust is recognized as non-operating revenue.

[5] Cash and cash equivalents:

For financial-reporting purposes, the Institute considers all highly liquid instruments purchased with a maturity of three months or less, when purchased, to be cash equivalents, except for those cash equivalent assets held as part of the investment portfolio.

[6] Investments:

The Institute's investments in equity securities, mutual funds, fixed income securities, and exchange traded funds are reported at their fair values in the statements of financial position based on quoted market prices. Cash and cash equivalents held as part of the investment portfolio are also included in the balances reported as investments.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

The Institute also has investments in limited partnerships and limited liability companies which are considered to be alternative investments, for which readily determinable fair values do not exist. The fair value of the alternative investments has been estimated based on the respective net asset value ("NAV") per share (or its equivalent unit) of each investment, as reported by the particular investment manager. Investments in limited partnerships and/or limited liability companies where NAV cannot be used as a practical expedient to fair value are valued based on the valuation policies and procedures of the general partners. The general partners perform oversight of the underlying positions, both on an investment level and from a risk perspective. The general partners are also responsible for ensuring that the investments are valued according to the policies and procedures adopted by the partnerships. The Institute places reliance upon those procedures, and it records those investments at fair value as determined by the general partners. Because of the complex management structures and nature of the underlying investments and the inherent uncertainty of the valuation of the alternative investments, the Institute's management and its various investment managers monitor their positions to reduce the risk of potential losses due to changes in fair values or the failure of counterparties to perform on a routine basis. Management believes the carrying amount of the investments in non-publicly traded securities is a reasonable estimate of their fair value. However, such estimated fair values may differ significantly from the values that would have been used had a ready market for these investments existed.

Certain of the Institute's investment managers enter into derivatives contracts held or issued for trading purposes. These investments are subject to various market risks, which arise from changes in securities values and other market conditions. As part of their overall trading strategies, the investment managers may engage in the purchases and sales of index and equity options, for the purpose of generating profit and/or reducing market risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

The Institute's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in net assets without donor restrictions unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost basis to proceeds at the time of disposition. Distributions from limited partnerships and limited liability companies that represent returns of contributed capital reduce the cumulative costs basis of the respective investment. Distributions received from limited partnerships and limited liability companies in excess of the Institute's cumulative cost basis are recognized as realized gains. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

Donated securities are recorded at their estimated fair values, or by their net asset values as determined by the Institute's management on the dates of donation. The Institute's policy is to sell the donated securities immediately, and, accordingly, for purposes of the statement of cash flows, donated securities and the proceeds generated from their sale are included within operating activities. With respect to donors' contributions of equity securities, which for example, are: (i) not readily marketable, (ii) the securities of private companies, or (iii) the securities of companies in liquidation, the Institute's policy is to record such items at appraised value, approximating fair value, at time of donation in the absence of readily determinable fair values.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

Investment expenses include the services of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Institute's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

In 2010, the Institute entered into a joint venture with the Ludwig Institute for Cancer Research Ltd. and formed a U.S. company named Cancer Vaccine Acceleration Company, LLC (“CVAC”). The members' initial capital contribution was $200. The purpose of the company is to obtain, hold, and develop intellectual property and other assets related to research and development of a vaccine for cancer, in furtherance of the respective charitable missions of the members.

[7] Office equipment and leasehold improvements:

Office equipment and leasehold improvements are stated at their original costs at the dates of acquisition, or if contributed, at their fair values at the dates of donation, net of accumulated depreciation. The Institute capitalizes items of property and equipment that have a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of three to ten years. Leasehold improvements are recorded at cost and are amortized over the life of the lease.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and when triggering events indicate that the fair value of the long-lived assets may be less than the carrying value, recognizes any impairment in the year of determination. There were no triggering events during 2022 or 2021 requiring management to test for impairment that would require any adjustments to property and equipment. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

[8] Beneficial interest in perpetual trust:

The Institute has been named as a beneficiary of a perpetual charitable trust which is administered by a third-party trustee. The trust was created independently by a donor and is administered by an outside agent designated by the donor; accordingly, the Institute has neither possession nor control over the assets of the trust.

The Institute reported the asset and recognized contribution revenue with donor restrictions, perpetual in nature, at the fair value of the Institute's interest in the trust assets. Distributions received on the trust assets are reported as revenue without donor restrictions in the statements of activities, in accordance with donor intent. Subsequent changes in fair value of the perpetual trust assets are recorded as a change in the value of perpetual trust in net assets with donor restrictions. At June 30, 2022 and 2021, the fair value of this trust was $669,540 and $806,477, respectively.

[9] Deferred rent obligation:

Rent expense is recorded on a straight-line basis over the term of the lease, and includes any concession and rent escalations over the life of the lease agreement. The difference between rental payments made under the terms of the lease agreement and rent expense calculated on a straight-line basis is recorded as a deferred rent obligation in the statements of financial position.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[10] Accrued vacation:

Based on their tenure, the Institute's employees are entitled to be paid for unused vacation time if they leave the Institute's employ. Accordingly, at each fiscal year-end, the Institute must recognize a liability for the amount that would be incurred if employees with such unused vacation time were to leave. At June 30, 2022 and 2021, this accrued vacation obligation was approximately $421,000 and $379,000, respectively, which is included in accounts payable and accrued expenses in the statements of financial position.

[11] Paycheck Protection Program loan payable:

On March 27, 2020, Congress enacted the Coronavirus Aid Relief, and Economic Security Act ("CARES Act"). The Paycheck Protection Program ("PPP") established by the CARES Act, implemented by the U.S. Small Business Administration ("SBA"), provided businesses, including certain not-for-profit organizations, with funds to pay payroll and qualifying expenditures during the coronavirus ("COVID-19") pandemic.

There are two acceptable methods for accounting for the PPP funds received under the CARES Act. Entities can elect to treat the funds as a loan or as a conditional contribution. The Institute has elected to record the PPP funds as a loan under the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") 470, Debt. During fiscal 2022, the Institute applied for and received loan forgiveness by the bank and the SBA. Accordingly, the Institute reported a gain on loan forgiveness in the statement of activities for fiscal 2022 (see Note E).

[12] Functional allocation of expenses:

The costs of providing the Institute's various programs and supporting services have been summarized on a functional basis in the statements of activities. The statements of functional expenses present expenses by function and natural classification. Accordingly, direct costs have been functionalized within the program and supporting services based on the nature of the expense. Indirect costs such as salaries, including payroll taxes and employee benefits, have been allocated based on the basis of time and effort by employees, and other indirect costs such as occupancy and depreciation have been allocated based on square footage.

[13] Income tax uncertainties:

The Institute follows the provisions of the FASB's ASC Topic 740, Income Taxes, relating to accounting and reporting for uncertainty in income taxes. For the Institute, these provisions could be applicable to the incurrence of unrelated business income. Because of the Institute's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Institute's financial statements.

[14] Net assets:

The net assets of the Institute and changes therein are reported as follows:

(i) Net assets without donor restrictions:

The Institute's net assets without donor restrictions represent those resources that are not subject to donor restrictions as to their use and are available for current operations. Funds designated by the Board of Trustees are to function as an endowment and remain without restrictions, subject to the discretion of the Board of Trustees.
**NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

[14] **Net assets: (continued)**

**(ii) Net assets with donor restrictions:**

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or the passage of time. Also included in net assets with donor restrictions are donor restrictions that are perpetual in nature and are subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity with the resultant income and net capital appreciation arising from the underlying assets to be used in the satisfaction of the wishes of those donors. When a donor's restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished or a Board appropriation has been made, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as "net assets released from restrictions." Contributions with donor restrictions received in a fiscal period during which the underlying restrictions are also met within the same fiscal period are recorded as net assets without donor restrictions in the statements of activities.

[15] **Contributions:**

Contributions to the Institute are recognized as revenue upon the receipt of either cash, other assets, or of unconditional pledges. Contributions are recorded as with donor restrictions if they are received with donor stipulations or time considerations as to their use. Conditional contributions are recognized when the donor's conditions have been met by requisite actions of the Institute's management or the necessary events have taken place, and if received in advance, are recognized in the statements of financial position as funds received in advance.

The Institute records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.

Gross proceeds paid by attendees at special events held as fundraising activities represent contribution revenue, as well as the payment of the direct cost of the benefit received by the attendee at the event. Special event income is reported net of the direct benefit to donors. Special event revenues, other than contributions, applicable to a current year are recognized as revenue in the year the special event takes place. Special event revenue for a future year's period is deferred and recognized when the event takes place.

The Institute has entered into various clinical research support agreements to conduct clinical trials of cancer immunotherapies. Contributions for clinical studies are recognized and recorded when the Institute recognizes the related expenses associated with the medical partners.

The Institute periodically assesses the collectability of its pledges receivable and other receivables using management's judgement regarding potential defaults; accordingly, management considers factors such as: (i) prior collection history; (ii) the type of contributions; and (iii) the nature of the clinical studies/trials, and provided allowances for anticipated losses, if any, when necessary.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[16] Contributed services:

For recognition of contributed services in the financial statements, such services must: (i) create or enhance non-financial assets, (ii) typically need to be acquired not provided by donation, (iii) require specialized skills, and (iv) be provided by individuals possessing these skills. Contributed services are recorded at their estimated fair value at the dates of donation and are reported as without donor restrictions in the statements of activities. The fair values of contributed services provided by the Institute's Scientific Advisory Council totaled $543,693 and $589,448 for fiscal-years 2022 and 2021, respectively, and these amounts have been recorded as revenue and expense in the statements of activities. Other contributed services provided to the Institute, such as those by volunteers, are not reported in the financial statements because they do not meet the criteria for recognition.

[17] Fellowships, investigatorships, and grants:

The Institute awards fellowships, investigatorships, and grants covering periods of one to four years for the purpose of medical research. These awards are recorded as expenses at the time they become unconditional.

[18] Science, medical and research information, and communications:

Science, medical and research information, and communications include costs primarily related to: (i) providing the public with information concerning cancer immunology, (ii) responding to inquiries from the public concerning cancer, and (iii) communicating with applicants and awardees. These awards are recorded as expenses at the time they become unconditional.

[19] Advertising costs:

The Institute expenses the costs of advertising as incurred. Advertising expenses were $617,905 and $416,569 during fiscal-years 2022 and 2021, respectively.

[20] Adoption of accounting pronouncement:

(i) Contributed nonfinancial assets:

In September 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-07, Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets, intended to improve transparency in the reporting of contributed nonfinancial assets, also known as gifts-in-kind, for not-for-profit organizations. The ASU requires a not-for-profit organization to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from contributions of cash or other financial assets. For each category of contributed nonfinancial assets recognized, the not-for-profit organization will need to disclose: (i) qualitative information about whether the contributed nonfinancial assets were either monetized or utilized during the reporting period. If utilized, a description of the programs or other activities in which those assets were used; (ii) the not-for-profit’s policy (if any) about monetizing rather than utilizing contributed nonfinancial assets; (iii) a description of any donor-imposed restrictions associated with the contributed nonfinancial assets; (iv) the valuation techniques and inputs used to arrive at a fair value measure, in accordance with the requirements in Topic 820, Fair Value Measurement, at initial recognition; and (v) the principal market (or most advantageous market) used to arrive at a fair value measure, if it is a market in which the recipient entity is prohibited by a donor-imposed restriction from selling or using the contributed nonfinancial assets. The amendments in this ASU will be applied on a retrospective basis and are effective for annual reporting periods beginning after June 15, 2021. Accordingly, the Institute adopted the standard for fiscal year ending June 30, 2022, and this accounting guidance did not have a material effect on the Institute’s financial statements.
NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[21] Upcoming accounting pronouncement:

(i) Leases:

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), as amended, which supersedes the current leasing guidance and upon adoption, will require lessees to recognize right-of-use assets and lease liabilities on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard is effective for the Institute for the annual period beginning after December 15, 2021, and can be early adopted. Upon the adoption of the guidance, operating leases are capitalized on the statement of financial position at the present value of lease payments. The statement of financial position amount recorded for existing leases at the date of adoption of ASU 2016-02 will be calculated using the applicable incremental borrowing rate at the date of adoption. The impact on the Institute’s financial statements is currently being evaluated. Information about the Institute’s undiscouted future lease payments and the timing of those payments is provided in Note N.

[22] Subsequent events:

The Institute evaluated subsequent events through September 23, 2022, the date on which the financial statements were available to be issued.

NOTE B - CONTRIBUTIONS AND GRANTS AND OTHER RECEIVABLES

[1] Contributions and grants receivable:

At each fiscal year-end, contributions and grants receivable were estimated to be received as follows:

<table>
<thead>
<tr>
<th>Gross amounts due in:</th>
<th>June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td>Less than one year</td>
<td>$ 15,263,692</td>
</tr>
<tr>
<td>One to five years</td>
<td>17,721,600</td>
</tr>
<tr>
<td></td>
<td>32,985,292</td>
</tr>
<tr>
<td>Reduction for contributions due in excess of one year, at a 1% discount rate</td>
<td>(264,573)</td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(5,083,246)</td>
</tr>
<tr>
<td></td>
<td><strong>$ 27,637,473</strong></td>
</tr>
</tbody>
</table>

Pledges receivable of $22,073,340 and $28,330,946 at June 30, 2022 and 2021, respectively, representing approximately 67% and 74%, respectively, of the total pledge balances at year end, and were due from three donors. Included in contribution revenue for fiscal-years 2022 and 2021, was an amount of $3,750,000 from one donor and $11,904,888 from one donor, respectively, which represented approximately 12% and 30%, respectively, of the total operating support and revenue for each fiscal year.
NOTE B - CONTRIBUTIONS AND GRANTS AND OTHER RECEIVABLES (CONTINUED)

[2] Bequests receivable:

Bequests receivable were $10,189 and $12,090 as of June 30, 2022 and June 30, 2021, respectively. All amounts are due within one year. All amounts are due within one year. Based on management’s past experience the receivables are expected to be fully collected, and, accordingly no allowance for doubtful accounts has been established.

[3] Other receivables:

At each year-end, other receivables consisted of amounts due to the Institute for exchange-type transactions. All amounts are due within one year. Based on management’s past experience, these receivables are expected to be fully collected, and, accordingly, no allowance for doubtful accounts has been established.

NOTE C - INVESTMENTS

At each fiscal year-end, investments consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2022</th>
<th></th>
<th>June 30, 2021</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fair Value</td>
<td>Cost</td>
<td>Fair Value</td>
<td>Cost</td>
</tr>
<tr>
<td>Cash equivalents</td>
<td>$2,419,066</td>
<td>$2,419,066</td>
<td>$1,463,888</td>
<td>$1,463,888</td>
</tr>
<tr>
<td>Equity securities</td>
<td>3,364,193</td>
<td>3,413,154</td>
<td>4,845,196</td>
<td>3,649,593</td>
</tr>
<tr>
<td>Mutual funds - equity securities</td>
<td>3,954,265</td>
<td>3,076,736</td>
<td>3,209,822</td>
<td>1,864,615</td>
</tr>
<tr>
<td>Mutual funds - fixed-income</td>
<td>3,531,860</td>
<td>3,765,243</td>
<td>3,706,683</td>
<td>3,483,604</td>
</tr>
<tr>
<td>Exchange traded funds - equity</td>
<td>11,607,631</td>
<td>12,038,814</td>
<td>5,409,777</td>
<td>3,914,453</td>
</tr>
<tr>
<td>Limited partnerships and limited liability companies [a]</td>
<td>64,598,585</td>
<td>45,207,071</td>
<td>56,205,116</td>
<td>32,211,414</td>
</tr>
<tr>
<td></td>
<td><strong>$89,475,600</strong></td>
<td><strong>$69,920,084</strong></td>
<td><strong>$74,840,482</strong></td>
<td><strong>$46,587,567</strong></td>
</tr>
</tbody>
</table>

[a] The limited partnerships and limited liability companies consist of hedge funds, private equities, and fund-of-funds that primarily invest in domestic and international securities, derivative contracts, and other investments across various classes, sectors, and geographies.
NOTE C - INVESTMENTS (CONTINUED)

During each fiscal year, the net investment return from investments and its classification in the accompanying statements of activities was as follows:

<table>
<thead>
<tr>
<th></th>
<th>Year Ended June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>$548,584</td>
</tr>
<tr>
<td>Net realized and unrealized gains</td>
<td>(5,123,589)</td>
</tr>
<tr>
<td>Investment advisory fees</td>
<td>(468,783)</td>
</tr>
<tr>
<td></td>
<td>(5,043,788)</td>
</tr>
<tr>
<td>Less: net investment allocation for current operations</td>
<td>(3,121,803)</td>
</tr>
<tr>
<td>Net investment (loss) income in excess of investment allocation</td>
<td>$(8,165,591)</td>
</tr>
</tbody>
</table>

The FASB's ASC Topic 820, Fair Value Measurements, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical assets, at the reporting date.

Level 2: Valuations are based on (i) quoted prices for similar assets in active markets, or (ii) quoted prices for those assets, or similar assets, in markets that are not active, or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.

Level 3: Valuations are based on pricing inputs that are unobservable and include situations where (i) there is little, if any, market activity for the assets, or (ii) the assets cannot be independently valued.

Certain of the Institute's investments are valued using NAV per share (or its equivalent unit) as a practical expedient of fair value. This applies to investments (i) which do not have a readily determinable fair value; and (ii) the financial statements of which were prepared by the respective investment managers, in a manner consistent with the measurement principles of either an investment company or an entity which has the attributes of an investment company. Investments that are valued using NAV per share (or its equivalent unit) are not required to be categorized within the fair-value hierarchy, and accordingly, have been appropriately excluded from the fair-value hierarchy.

The availability of relevant market data is monitored by the Institute's management to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period.
NOTE C - INVESTMENTS (CONTINUED)

The following tables summarize the fair values of the Institute's investments and other assets at each fiscal year-end, in accordance with ASC Topic 820 valuation fair-value levels:

### June 30, 2022

<table>
<thead>
<tr>
<th>Amounts Within Fair Value Hierarchy</th>
<th>Measured at</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 3</td>
</tr>
<tr>
<td>Investments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash equivalents</td>
<td>$2,419,066</td>
<td>$ -</td>
</tr>
<tr>
<td>Equity securities</td>
<td>3,364,193</td>
<td>-</td>
</tr>
<tr>
<td>Mutual funds – equity securities</td>
<td>3,954,265</td>
<td>-</td>
</tr>
<tr>
<td>Mutual funds - fixed-income</td>
<td>3,531,860</td>
<td>-</td>
</tr>
<tr>
<td>ETFs - equity</td>
<td>11,607,631</td>
<td>-</td>
</tr>
<tr>
<td>Limited partnerships and LLCs</td>
<td>-</td>
<td>257,755</td>
</tr>
<tr>
<td>Total</td>
<td>$24,877,015</td>
<td>257,755</td>
</tr>
<tr>
<td>Other assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beneficial interest in perpetual trust</td>
<td>-</td>
<td>669,540</td>
</tr>
<tr>
<td>Total</td>
<td>$24,877,015</td>
<td>927,295</td>
</tr>
</tbody>
</table>

### June 30, 2021

<table>
<thead>
<tr>
<th>Amounts Within Fair Value Hierarchy</th>
<th>Measured at</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 3</td>
</tr>
<tr>
<td>Investments:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash equivalents</td>
<td>$1,463,888</td>
<td>$ -</td>
</tr>
<tr>
<td>Equity securities</td>
<td>4,845,196</td>
<td>-</td>
</tr>
<tr>
<td>Mutual funds – equity securities</td>
<td>3,209,822</td>
<td>-</td>
</tr>
<tr>
<td>Mutual funds - fixed-income</td>
<td>3,706,683</td>
<td>-</td>
</tr>
<tr>
<td>ETFs - equity</td>
<td>5,409,777</td>
<td>-</td>
</tr>
<tr>
<td>Limited partnerships and LLCs</td>
<td>-</td>
<td>451,756</td>
</tr>
<tr>
<td>Total</td>
<td>18,635,366</td>
<td>451,756</td>
</tr>
<tr>
<td>Other assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beneficial interest in perpetual trust</td>
<td>-</td>
<td>806,477</td>
</tr>
<tr>
<td>Total</td>
<td>18,635,366</td>
<td>1,258,233</td>
</tr>
</tbody>
</table>
NOTE C - INVESTMENTS (CONTINUED)

During fiscal-years 2022 and 2021, the Institute purchased approximately $0 and $2,869 of Level 3 investments, respectively. During fiscal-years 2022 and 2021, the Institute redeemed approximately $178,637 and $249,899 of Level 3 investments, respectively.

The following table lists investments in other investment companies by major category at June 30, 2022:

<table>
<thead>
<tr>
<th></th>
<th>Fair Value</th>
<th>Unfunded Commitments</th>
<th>Redemption Frequency</th>
<th>Redemption Notice Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private equity funds</td>
<td>$ 32,517,731</td>
<td>$ 12,726,947</td>
<td>N/A</td>
<td>Upon liquidation</td>
</tr>
<tr>
<td>Multiple hedge funds</td>
<td>7,509,165</td>
<td>-</td>
<td>Quarterly</td>
<td>30-60 Days</td>
</tr>
<tr>
<td>Multiple hedge fund</td>
<td>2,455,112</td>
<td>-</td>
<td>Monthly</td>
<td>30-90 Days</td>
</tr>
<tr>
<td>Fund-of-funds</td>
<td>14,507,433</td>
<td>-</td>
<td>Quarterly</td>
<td>95 Days</td>
</tr>
<tr>
<td>Fund-of-funds</td>
<td>7,609,144</td>
<td>-</td>
<td>Monthly</td>
<td>95 Days</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 64,598,585</td>
<td>$ 12,726,947</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quantitative information regarding unobservable inputs developed by the Institute and assumptions used to measure the investments in limited partnerships, and the beneficial interest in perpetual trust as of June 30, 2022 are as follows:

<table>
<thead>
<tr>
<th>Type</th>
<th>Fair Value</th>
<th>Valuation Techniques</th>
<th>Significant Unobservable Inputs</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited partnerships</td>
<td>$ 257,755</td>
<td>Market approach through valuation of underlying securities</td>
<td>Fair value of investment assets</td>
<td>0.93%</td>
</tr>
<tr>
<td>Beneficial interest in</td>
<td>$ 669,540</td>
<td>Market approach through valuation of underlying securities</td>
<td>Fair value of trust assets</td>
<td>8.00%</td>
</tr>
<tr>
<td>perpetual trust</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NOTE D - PROPERTY AND EQUIPMENT

At each fiscal year-end, property and equipment consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2022</th>
<th>June 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office equipment</td>
<td>$ 548,629</td>
<td>$ 524,762</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>110,205</td>
<td>91,569</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$ 658,834</td>
<td>616,331</td>
</tr>
<tr>
<td>Less: accumulated depreciation and amortization</td>
<td>(516,625)</td>
<td>(471,461)</td>
</tr>
<tr>
<td><strong>Adjusted Total</strong></td>
<td>$ 142,209</td>
<td>$ 144,870</td>
</tr>
</tbody>
</table>
NOTE E - PPP LOAN PAYABLE

On May 1, 2020, the Institute received $710,150 in funds from the PPP and is reported as a Paycheck Protection Program loan payable in the statement of financial position at June 30, 2021. Neither principle nor interest is due for a six-month deferral period through November 2020. This loan may be forgiven subject to bank approval in accordance with SBA guidelines. During fiscal 2022, the Institute applied for and received forgiveness of the PPP loan from the bank and SBA. Accordingly, the Institute reported a gain on loan forgiveness in the statement of activities for fiscal 2022.

NOTE F - GRANTS AND FELLOWSHIPS PAYABLE

At each fiscal year-end, grants and fellowships payable consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2022</th>
<th>June 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Due to be paid within one years</td>
<td>$26,313,024</td>
<td>$35,442,972</td>
</tr>
<tr>
<td>Due to be paid between two and five years</td>
<td>$37,271,089</td>
<td>$35,490,923</td>
</tr>
<tr>
<td>Less: present value discount of up to 1%</td>
<td>(594,650)</td>
<td>(593,436)</td>
</tr>
<tr>
<td></td>
<td>$62,989,463</td>
<td>$70,340,459</td>
</tr>
</tbody>
</table>

NOTE G - NET ASSETS WITH DONOR RESTRICTIONS

At each fiscal year-end, net assets with donor restrictions consisted of the following:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2022</th>
<th>June 30, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose restricted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical and laboratory research</td>
<td>$20,655,562</td>
<td>$21,858,823</td>
</tr>
<tr>
<td>Perpetual in nature:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fellowships</td>
<td>2,878,390</td>
<td>2,878,390</td>
</tr>
<tr>
<td>Other</td>
<td>669,540</td>
<td>806,477</td>
</tr>
<tr>
<td></td>
<td>3,547,930</td>
<td>3,684,867</td>
</tr>
<tr>
<td></td>
<td>$24,203,492</td>
<td>$25,543,690</td>
</tr>
</tbody>
</table>

Included within net assets with donor restrictions for clinical and laboratory research is accumulated endowment income reserved for appropriation at both June 30, 2022 and 2021 of $689,333 and $1,269,699, respectively.

Net assets released from restrictions were in fulfillment of clinical and laboratory research of $2,149,562 and $4,158,974 for the fiscal-years ended June 30, 2022 and 2021, respectively.
NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS

[1] The endowment:

The Institute's endowment funds consists of individual funds established for a variety of purposes, consisting of both donor-restricted and Board-designated funds. As required by U.S. GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

[2] Interpretation of relevant law:

As discussed in Note A[14] (ii), NYPMIFA is applicable to all of the Institute's institutional funds, including its donor-restricted endowment funds. The Board of Trustees will continue to adhere to NYPMIFA's requirements.

[3] Endowment net-asset composition by type of fund, as of each fiscal year-end:

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2022</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Without Donor</td>
<td>Amounts Subject to</td>
<td>Amounts Held in</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>Restrictions</td>
<td>Appropriation</td>
<td>Perpetuity</td>
<td></td>
</tr>
<tr>
<td>Donor-restricted endowment funds</td>
<td>$ -</td>
<td>$ 689,333</td>
<td>$ 3,547,930</td>
<td>$ 4,237,263</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>$ 5,614,906</td>
<td>-</td>
<td>-</td>
<td>$ 5,614,906</td>
</tr>
<tr>
<td>Total funds</td>
<td>$ 5,614,906</td>
<td>$ 689,333</td>
<td>$ 3,547,930</td>
<td>$ 9,852,169</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>June 30, 2021</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Without Donor</td>
<td>Amounts Subject to</td>
<td>Amounts Held in</td>
<td>Total</td>
</tr>
<tr>
<td></td>
<td>Restrictions</td>
<td>Appropriation</td>
<td>Perpetuity</td>
<td></td>
</tr>
<tr>
<td>Donor-restricted endowment funds</td>
<td>$ 5,931,228</td>
<td>$ 1,269,699</td>
<td>$ 3,684,867</td>
<td>$ 4,954,566</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>$ 5,931,228</td>
<td>-</td>
<td>-</td>
<td>$ 5,931,228</td>
</tr>
<tr>
<td>Total funds</td>
<td>$ 5,931,228</td>
<td>$ 1,269,699</td>
<td>$ 3,684,867</td>
<td>$ 10,885,794</td>
</tr>
</tbody>
</table>
NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[4] Changes in endowment net assets, during each fiscal year:

<table>
<thead>
<tr>
<th>Year Ended June 30, 2022</th>
<th>Without Donor Restrictions</th>
<th>Amounts Subject to Appropriation</th>
<th>Amounts Held in Perpetuity</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets, beginning of year</td>
<td>$5,931,228</td>
<td>$1,269,699</td>
<td>$3,684,867</td>
<td>$10,885,794</td>
</tr>
<tr>
<td>Investment return:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>37,078</td>
<td>18,563</td>
<td></td>
<td>55,641</td>
</tr>
<tr>
<td>Net depreciation (realized and unrealized)</td>
<td>(372,900)</td>
<td>(598,929)</td>
<td>(136,937)</td>
<td>(1,008,766)</td>
</tr>
<tr>
<td>Total investment return</td>
<td>(335,822)</td>
<td>(580,366)</td>
<td>(136,937)</td>
<td>(1,053,125)</td>
</tr>
<tr>
<td>Contributions</td>
<td>19,500</td>
<td></td>
<td></td>
<td>19,500</td>
</tr>
<tr>
<td>Endowment net assets, end of year</td>
<td>$5,614,906</td>
<td>$689,333</td>
<td>$3,547,930</td>
<td>$9,852,169</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year Ended June 30, 2021</th>
<th>Without Donor Restrictions</th>
<th>Amounts Subject to Appropriation</th>
<th>Amounts Held in Perpetuity</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets, beginning of year</td>
<td>$4,539,701</td>
<td>$237,406</td>
<td>$3,532,204</td>
<td>$8,309,311</td>
</tr>
<tr>
<td>Investment return:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>19,375</td>
<td>16,838</td>
<td></td>
<td>36,213</td>
</tr>
<tr>
<td>Net appreciation (realized and unrealized)</td>
<td>1,347,972</td>
<td>1,015,455</td>
<td>152,663</td>
<td>2,516,090</td>
</tr>
<tr>
<td>Total investment return</td>
<td>1,367,347</td>
<td>1,032,293</td>
<td>152,663</td>
<td>2,552,303</td>
</tr>
<tr>
<td>Contributions</td>
<td>24,180</td>
<td></td>
<td></td>
<td>24,180</td>
</tr>
<tr>
<td>Endowment net assets, end of year</td>
<td>$5,931,228</td>
<td>$1,269,699</td>
<td>$3,684,867</td>
<td>$10,885,794</td>
</tr>
</tbody>
</table>

Amounts subject to appropriation represent that portion of allocated investment income, derived from endowment assets held in perpetuity that has not yet been appropriated for expenditure by the Board of Trustees.
NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historic dollar-value of the donor’s original restricted contribution to be held in perpetuity. Under the terms of NYPMIFA, the Institute has no responsibility to restore such decreases in value. There were no such deficiencies at June 30, 2022 and 2021.

[6] Return objectives and risk parameters:

The Institute has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs and other functions supported by its Board-designated endowment, while seeking to maintain the purchasing power of the Board-designated endowment assets. Under this policy, as approved by the Board of Trustees, the Board-designated endowment assets are invested in a manner that is intended to produce results that obtain a better rate of return than the major investment indexes. The two donor-restricted funds (other than the perpetual trust) generate income that is fully utilized each year for their specified programmatic activities.

[7] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Institute relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Institute targets a diversified asset allocation within prudent risk constraints.

[8] Spending policy and related objectives:

(i) Endowment appropriation:

The appropriation from the endowment is based on the earnings in the respective year.

(ii) Investment pool appropriation:

The Board of Trustees’ authorized spending from the Institute’s investment pool (for restricted funds and for general operations) is 5% of the average market value of the Institute’s investment portfolio over the preceding three years. In establishing this policy, the Institute considered the long-term expected return on its investment. Accordingly, over the long term, the Institute expects the current spending policy to allow its portfolio to maintain the purchasing power of the Board-designated endowment assets, as well as to provide additional real growth through investment returns. The 5% authorized spending rate was used in both fiscal-years ended June 30, 2022 and 2021. During fiscal-years ended June 30, 2022 and 2021, there were no amounts appropriated.
NOTE I - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Institute's financial assets as of the statement of financial position date, reduced by amounts not available for general use within one year of June 30, 2022 because of contractual or donor-imposed restrictions or internal designations.

<table>
<thead>
<tr>
<th>Year Ended</th>
<th>June 30,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$12,037,142</td>
</tr>
<tr>
<td>Contributions and grants receivable, net</td>
<td>28,637,473</td>
</tr>
<tr>
<td>Bequests receivable</td>
<td>10,189</td>
</tr>
<tr>
<td>Other receivables</td>
<td>39,970</td>
</tr>
<tr>
<td>Investments (net of private placements with redemption restrictions)</td>
<td>56,957,869</td>
</tr>
<tr>
<td>Total financial assets available within one year</td>
<td>$97,682,643</td>
</tr>
</tbody>
</table>

Less:
- Amounts unavailable for general expenditures within one year, due to:
  - Restrictions by donors with purpose restrictions | (20,655,562) | (21,858,823) |
  - Restricted by donors that are perpetual in nature | (2,878,390) | (2,878,390) |
  - Total amounts unavailable for general expenditure within one year | (23,533,952) | (24,737,213) |

Amounts unavailable to management without Board approval:
  - Board-designated endowment | (5,614,906) | (5,931,228) |
  - Total financial assets available to meet cash needs for general expenditures within one year | $68,533,785 | $91,223,486 |

Liquidity policy:
The Institute has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Additionally, the Institute has a Board-designated endowment whereby amounts could be made available for current operations, if necessary; however, the Institute does not intend to spend these funds for purposes other than those approved by the Board of Trustees.

NOTE J - ALLOCATION OF JOINT COSTS OF INFORMATION MATERIALS

The Institute incurred joint costs in the placement of advertisements that amounted to $60,735 and $59,601 in fiscal-years 2022 and 2021, respectively. The Institute allocated such costs as follows:

<table>
<thead>
<tr>
<th>June 30,</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td>Marketing and development</td>
<td>$45,551</td>
</tr>
<tr>
<td>Science, medical and research information and communications</td>
<td>15,184</td>
</tr>
<tr>
<td>Total</td>
<td>$60,735</td>
</tr>
</tbody>
</table>
NOTE K - EMPLOYEE-BENEFIT PLAN

The Institute has a defined-contribution retirement plan, which provides for the Institute to make monthly contributions of at least 5% of the compensation of eligible employees. In addition, the Institute may contribute to the plan a discretionary amount equal to a percentage of compensation which is to be determined each plan year by the Institute. The plan also allows the participants to make voluntary contributions up to the maximum allowed by federal tax law. During fiscal-years 2022 and 2021, the Institute contributed amounts of approximately $305,000 and $295,000, respectively, to the plan.

NOTE L - CREDIT RISK

Financial instruments that potentially subject the Institute to concentrations of credit risk consist principally of cash and cash-equivalents deposited in financial institutions in amounts which, from time to time, may exceed federal insurance limits. However, based on the current Federal Deposit Insurance Coverage, management believes that the Institute does not face a significant risk of loss on these accounts that might result from the failures of the financial institutions.

NOTE M - CONTRIBUTED SCIENTIFIC ADVISORY SERVICES

During the fiscal year, the value of scientific advisory services contributed to the Organization consisted of the following:

<table>
<thead>
<tr>
<th>Non-Financial Contribution Category</th>
<th>Type of Contribution</th>
<th>Valuation</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Advisory Services</td>
<td>Advisory Services</td>
<td>Estimated market rate for similar services in the same location</td>
<td>$543,693</td>
<td>$589,448</td>
</tr>
</tbody>
</table>
NOTE N - COMMITMENTS AND OTHER UNCERTAINTY

Lease obligation:
The Institute is obligated under a 124-month lease agreement for office space, expiring in January 2028. The lease is subject to escalation for the Institute's pro-rata share of increases in real estate taxes and operating expenses. Concurrent with the authorization of the lease agreement, the Institute entered into a sublease agreement for a portion of its office space, also expiring in January 2028. In September 2017, the Institute entered into lease agreements for office equipment, which expire in September 2022. Minimum future estimated lease payments and lease income are as follows:

<table>
<thead>
<tr>
<th>Year Ending June 30,</th>
<th>Lease Payments</th>
<th>Lease Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>$553,273</td>
<td>($153,980)</td>
</tr>
<tr>
<td>2024</td>
<td>556,842</td>
<td>(158,467)</td>
</tr>
<tr>
<td>2025</td>
<td>556,842</td>
<td>(161,426)</td>
</tr>
<tr>
<td>2026</td>
<td>556,842</td>
<td>(164,444)</td>
</tr>
<tr>
<td>2027</td>
<td>556,842</td>
<td>(168,471)</td>
</tr>
<tr>
<td>Thereafter</td>
<td>139,211</td>
<td>(98,276)</td>
</tr>
<tr>
<td>Total</td>
<td>$2,919,852</td>
<td>($905,064)</td>
</tr>
</tbody>
</table>

Other uncertainty:
The extent of the impact of the coronavirus ("COVID-19") pandemic on the Institute's operations and financial performance had a non-material impact on the Institute. The Institute will continue to monitor future developments of the outbreak and any potential impact brought by the duration of the COVID-19 pandemic on the Institute's operations.